US EditionOff-label, on target: new hope for children with inflammatory bowel disease - Journal of Cyber Policy
Summary by Journal of Cyber Policy
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Off-label, on target: new hope for children with inflammatory bowel disease - Journal of Cyber Policy
FAYETTEVILLE, GA, UNITED STATES, August 19, 2025 /EINPresswire.com/ — Off-label treatments are offering new hope to children battling inflammatory bowel disease (IBD), especially when conventional therapies fall short. A comprehensive new review explores the real-world application of biologics and small molecule drugs originally approved for adults—such as ustekinumab, vedolizumab, upadacitinib, and ozanimod—in pediatric IBD cases. These alterna…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
